Although ABT199 is often considered to be effective only in BCL2 dependent cancers, our study indicates that it can also be used to increase cisplatin effectiveness in TNBC cells that express both BCL(X)L and BCL2, albeit at higher concentration than WEHI-539. The gene discussed is BCL2; the disease is cancer.